Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 12:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,662 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Diabetes Mellitus Type I Clear all

Conditions: Type 1 Diabetes
Interventions: Atomoxetine, Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Solid Tumor, Lymphoma
Interventions: CX-072, ipilimumab, vemurafenib; Drug
Lead sponsor: CytomX Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 16
States / cities: Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 10 more

Conditions: Type 1 Diabetes
Interventions: Vitamin D, Placebo; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 4 Years to 18 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Type 1 Diabetes
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 1 Year to 5 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Solid Tumor, Unresectable or Metastatic Melanoma
Interventions: CX-072, Ipilimumab; Drug
Lead sponsor: CytomX Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 14
States / cities: Duarte, California • Los Angeles, California • Coeur d'Alene, Idaho + 8 more

Conditions: Type 1 Diabetes
Interventions: Medtronic MiniMed Closed Loop (CL) System, Snacking; Device · Other
Lead sponsor: Yale University; Other
Eligibility: 13 Years to 44 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetes, Type 1 Diabetes
Interventions: Unified protocol for cognitive behavioral therapy (UP-CBT), Continuous Glucose Monitoring (CGM); Behavioral · Device
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years to 64 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • The Bronx, New York

Conditions: Type 1 Diabetes
Interventions: interoperable Artificial Pancreas System (iAPS), Sensor-Augmented Pump (SAP)/Predictive Low Glucose Suspend (PLGS); Device · Other
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 5
States / cities: Santa Barbara, California • Stanford, California • Boston, Massachusetts + 2 more

Conditions: Type 1 Diabetes, Obesity
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: New York, New York

Conditions: Type 1 Diabetes
Interventions: Mylan's insulin glargine, Lantus®; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 72
States / cities: Bell Gardens, California • Fresno, California • Greenbrae, California + 64 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Dapagliflozin 5mg, Placebo; Drug
Lead sponsor: The Hospital for Sick Children; Other
Eligibility: 12 Years to 18 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Type 1 Diabetes Mellitus
Interventions: Group education sessions; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 13 Years to 18 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetes Mellitus, Type 1
Interventions: Teens-Connect, Planet D; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 11 Years to 14 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: New Haven, Connecticut • Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus Type 1
Interventions: Allogeneic Pancreatic Endocrine Cell Clusters; Biological
Lead sponsor: Seraxis; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Type 1 Diabetes Mellitus
Interventions: TAK-329, Insulin, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Type 1 Diabetes Mellitus
Interventions: PolyTregs+IL-2; Biological
Lead sponsor: Jeffrey Bluestone; Other
Eligibility: 18 Years to 45 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 2
States / cities: San Francisco, California • New Haven, Connecticut

Conditions: Diabetes Mellitus, Type 1
Interventions: HDV insulin lispro 100 UNT/ML, Insulin Lispro 100 UNT/ML; Drug
Lead sponsor: Diasome Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Aurora, Colorado • Miami, Florida • Morehead City, North Carolina + 1 more

Conditions: Type 1 Diabetes
Interventions: CLC + BAM, CLC + ABC; Device
Lead sponsor: Sue Brown; Other
Eligibility: 18 Years to 70 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Melanoma
Interventions: Nivolumab, Ipilimumab; Biological
Lead sponsor: NYU Langone Health; Other
Eligibility: 16 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Type1 Diabetes Mellitus
Interventions: HDV insulin lispro 100 UNIT/mL, Insulin Lispro 100 Units/mL; Drug
Lead sponsor: Diasome Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Type 1 Diabetes
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 2 Years to 26 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Type 1 Diabetes
Interventions: MiniMed 780G System; Device
Lead sponsor: Medtronic MiniMed, Inc.; Industry
Eligibility: 7 Years to 80 Years
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 19
States / cities: Palo Alto, California • San Diego, California • Aurora, Colorado + 15 more

Conditions: Type 1 Diabetes Mellitus
Interventions: teplizumab, Placebo; Biological
Lead sponsor: Provention Bio, Inc.; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 34
States / cities: San Diego, California • San Francisco, California • Walnut Creek, California + 30 more

Conditions: Diabetes (DM)
Interventions: Not listed
Lead sponsor: 4YouandMe; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine

PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

Effect of Vitamin D on the Honeymoon Period in Children and Adolescents With Type 1 Diabetes

Prospective Study of the Impact of Insulin Pump Therapy in Young Children With Type 1 Diabetes

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

Preventing Hypoglycemia During Exercise With Proactive Snacking on Closed Loop

Telemedicine-Delivered Unified Protocol for Cognitive Behavioral Therapy for Anxiety and Depression

The International Diabetes Closed Loop (iDCL) Trial: Protocol 4

PET Scan Imaging of Beta Cell Mass

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)

Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial

High Risk Youth With Poorly-controlled Diabetes

Teens-Connect: Preventive Psycho-education for Transitioning Teens With Diabetes

A Study of the Safety and Efficacy of Pancreatic Endocrine Cell Clusters Implanted Into the Omentum of Type 1 Diabetes Patients With Severe Hypoglycemia

TAK-329 Glucose Clamp Study

T1DM Immunotherapy Using Polyclonal Tregs + IL-2

Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control

Adaptive Biobehavioral Control (ABC) in a Closed-Loop System

Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma

21 Day Comparison of Continuous Insulin Infusion Using HDV Insulin to Standard Insulin in Type 1 Diabetes Mellitus

Accuracy of Continuous Glucose Monitors During the Perioperative Period in Youth With Type 1 Diabetes

Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev®

Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab

BETA - Pilot Study